儿科制剂：设计与开发。
Paediatric Formulation: Design and Development.
机构信息
Department of Pharmacy-Pharmaceutical Sciences, University of Bari Aldo Moro, 70125 Bari, Italy.
出版信息
Int J Mol Sci. 2020 Sep 27;21(19):7118. doi: 10.3390/ijms21197118.
Abstract
The development of medicines designed for children can be challenging since this distinct patient population requires specific needs. A formulation designed for paediatric patients must consider the following aspects: patient population variability; dose flexibility; route of administration; patient compliance; drug and excipient tolerability. The purpose of this Special Issue entitled "Paediatric Formulation: Design and Development" is to provide an update on both state-of-the-art methodology and operational challenges in the design and development of paediatric formulations. It aims at re-evaluating what is needed for more progress in the design and development of age-appropriate treatments for paediatric diseases, focusing on: formulation development; drug delivery design; efficacy, safety, and tolerability of drugs and excipients. This editorial, briefly, summarizes the objects of nine original research and review papers published in this Special Issue.
摘要
专为儿童设计的药物的开发可能具有挑战性，因为这一特定的患者群体有特殊的需求。专为儿科患者设计的制剂必须考虑以下几个方面：患者群体的可变性；剂量的灵活性；给药途径；患者顺应性；药物和赋形剂的耐受性。本期特刊题为“儿科制剂：设计与开发”，旨在提供最新的关于儿科制剂设计和开发的最先进方法和操作挑战方面的信息。它旨在重新评估在设计和开发适合儿科疾病的年龄适当治疗方法方面需要做些什么，重点是：制剂开发；药物传递设计；药物和赋形剂的疗效、安全性和耐受性。这篇社论简要总结了本期特刊中发表的九篇原始研究和综述论文的研究对象。
相似文献
1
Paediatric Formulation: Design and Development.儿科制剂：设计与开发。
Int J Mol Sci. 2020 Sep 27;21(19):7118. doi: 10.3390/ijms21197118.
2
Best practices for selection of excipients for paediatrics - Workshop reflection.辅料选择的最佳实践 - 专题研讨会反思。
Eur J Pharm Biopharm. 2021 Mar;160:77-81. doi: 10.1016/j.ejpb.2020.12.021. Epub 2021 Jan 2.
3
Safe, swallowable and palatable paediatric mini-tablet formulations for a WHO model list of essential medicines for children compound - A promising starting point for future PUMA applications.安全、可吞咽、可口的儿科迷你片剂制剂，用于世界卫生组织儿童基本药物标准清单组合 - 未来 PUMA 应用的有希望起点。
Eur J Pharm Biopharm. 2020 Nov;156:11-19. doi: 10.1016/j.ejpb.2020.08.014. Epub 2020 Aug 29.
4
Playing hide and seek with poorly tasting paediatric medicines: do not forget the excipients.与味道不佳的儿科药物玩捉迷藏：别忘了赋形剂。
Adv Drug Deliv Rev. 2014 Jun;73:14-33. doi: 10.1016/j.addr.2014.02.012. Epub 2014 Mar 12.
5
Paediatric Drug Development and Formulation Design-a European Perspective.儿科药物研发与制剂设计——欧洲视角
AAPS PharmSciTech. 2017 Feb;18(2):241-249. doi: 10.1208/s12249-016-0558-3. Epub 2016 Jun 7.
6
Unmet technological demands in orodispersible films for age-appropriate paediatric drug delivery.适合儿科药物递送的口崩膜中未满足的技术需求。
Drug Deliv Transl Res. 2024 Apr;14(4):841-857. doi: 10.1007/s13346-023-01451-3. Epub 2023 Nov 13.
7
Formulation of medicines for children.儿童用药制剂
Br J Clin Pharmacol. 2005 Jun;59(6):674-6. doi: 10.1111/j.1365-2125.2005.02410.x.
8
Age-Appropriate Formulations Including Pharmaceutical Excipients in Neonatal Medicines.适用于新生儿药物的含药用辅料的年龄适宜配方。
Curr Pharm Des. 2017;23(38):5779-5789. doi: 10.2174/1381612823666170926122613.
9
Selecting appropriate excipients for paediatric dosage form - Paediatric excipients risk assessment (PERA) framework - Part 1.选择适合儿科剂型的赋形剂 - 儿科赋形剂风险评估 (PERA) 框架 - 第 1 部分。
Eur J Pharm Biopharm. 2024 Oct;203:114458. doi: 10.1016/j.ejpb.2024.114458. Epub 2024 Aug 17.
10
Conference report: formulating better medicines for children: 4th European Paediatric Formulation Initiative conference.会议报告：为儿童研发更优质药物：第4届欧洲儿科制剂倡议会议
Ther Deliv. 2013 Jan;4(1):21-5. doi: 10.4155/tde.12.135.
引用本文的文献
1
Metronidazole Suspension for Paediatric Use in Developing Countries: Formulation, Quality, and Stability.发展中国家儿童用甲硝唑悬浮液：配方、质量与稳定性
Pharmaceutics. 2025 Jun 17;17(6):787. doi: 10.3390/pharmaceutics17060787.
2
Clinical data required for the approval of pediatric pharmaceuticals in Japan.日本儿科药品批准所需的临床数据。
BMC Pediatr. 2025 Apr 14;25(1):289. doi: 10.1186/s12887-025-05646-0.
3
Oral Gels as an Alternative to Liquid Pediatric Suspensions Compounded from Commercial Tablets.口腔凝胶作为由市售片剂配制的液体儿科混悬剂的替代品。
Pharmaceutics. 2024 Sep 20;16(9):1229. doi: 10.3390/pharmaceutics16091229.
4
Questionnaire Study to Investigate the Preferences of Children, Parents, and Healthcare Professionals for Different Formulations of Oral Medicinal Products.调查儿童、家长和医疗保健专业人员对不同剂型口服药品偏好的问卷调查研究
Pharmaceutics. 2024 Apr 8;16(4):515. doi: 10.3390/pharmaceutics16040515.
5
3D Printing Technology Based on Versatile Gelatin-Carrageenan Gel System for Drug Formulations.基于多功能明胶-卡拉胶凝胶体系的3D打印技术用于药物制剂
Pharmaceutics. 2023 Apr 11;15(4):1218. doi: 10.3390/pharmaceutics15041218.
6
Palatability Assessment of Carbocysteine Oral Solution Strawberry Taste Versus Carbocysteine Oral Solution Mint Taste: A Blinded Randomized Study.羧甲司坦口服溶液草莓味与羧甲司坦口服溶液薄荷味的口感评估：一项双盲随机研究。
Front Pharmacol. 2022 Feb 28;13:822086. doi: 10.3389/fphar.2022.822086. eCollection 2022.
本文引用的文献
1
Optimal Design, Characterization and Preliminary Safety Evaluation of an Edible Orodispersible Formulation for Pediatric Tuberculosis Pharmacotherapy.优化设计、特性描述及儿科结核病药物治疗用可口服速溶制剂的初步安全性评价
Int J Mol Sci. 2020 Aug 10;21(16):5714. doi: 10.3390/ijms21165714.
2
Bcr-Abl Tyrosine Kinase Inhibitors in the Treatment of Pediatric CML.Bcr-Abl 酪氨酸激酶抑制剂在儿科 CML 治疗中的应用。
Int J Mol Sci. 2020 Jun 23;21(12):4469. doi: 10.3390/ijms21124469.
3
Taste masking of propranolol hydrochloride by microbeads of EUDRAGIT® E PO obtained with prilling technique for paediatric oral administration.采用制粒技术将 EUDRAGIT® E PO 微球用于盐酸普萘洛尔的掩味，便于儿科口服。
Int J Pharm. 2020 Jan 25;574:118922. doi: 10.1016/j.ijpharm.2019.118922. Epub 2019 Dec 10.
4
Thiolated hydroxypropyl-β-cyclodextrin as mucoadhesive excipient for oral delivery of budesonide in liquid paediatric formulation.巯基化羟丙基-β-环糊精作为黏液附着促进剂用于布地奈德口服液体制剂的口服传递。
Int J Pharm. 2019 Dec 15;572:118820. doi: 10.1016/j.ijpharm.2019.118820. Epub 2019 Nov 7.
5
Classification of WHO Essential Oral Medicines for Children Applying a Provisional Pediatric Biopharmaceutics Classification System.应用临时儿科生物药剂学分类系统对世界卫生组织儿童基本口服药物进行分类
Pharmaceutics. 2019 Oct 31;11(11):567. doi: 10.3390/pharmaceutics11110567.
6
How to Modify Drug Release in Paediatric Dosage Forms? Novel Technologies and Modern Approaches with Regard to Children's Population.如何改变儿科剂型中的药物释放？针对儿童人群的新型技术和现代方法。
Int J Mol Sci. 2019 Jun 29;20(13):3200. doi: 10.3390/ijms20133200.
7
Making Medicines Baby Size: The Challenges in Bridging the Formulation Gap in Neonatal Medicine.将药物制成婴儿剂型：新生儿医学中制剂差距的挑战。
Int J Mol Sci. 2019 May 31;20(11):2688. doi: 10.3390/ijms20112688.
8
Unveiling the Efficacy, Safety, and Tolerability of Anti-Interleukin-1 Treatment in Monogenic and Multifactorial Autoinflammatory Diseases.揭示抗白细胞介素-1 治疗在单基因和多因素自身炎症性疾病中的疗效、安全性和耐受性。
Int J Mol Sci. 2019 Apr 17;20(8):1898. doi: 10.3390/ijms20081898.
9
Development and Palatability Assessment of Norvir® (Ritonavir) 100 mg Powder for Pediatric Population.研制及口感评估奈伟拉平（利托那韦）100 毫克儿科人群用药散剂。
Int J Mol Sci. 2019 Apr 6;20(7):1718. doi: 10.3390/ijms20071718.
10
Combining Mechanochemistry and Spray Congealing for New Praziquantel Pediatric Formulations in Schistosomiasis Treatment.将机械化学与喷雾凝结相结合，为血吸虫病治疗开发新的吡喹酮儿科制剂。
Int J Mol Sci. 2019 Mar 12;20(5):1233. doi: 10.3390/ijms20051233.
Zotero 插件